Bio Cost Of Revenue vs Total Revenue Analysis
TECH Stock | USD 75.36 0.02 0.03% |
Bio Techne financial indicator trend analysis is way more than just evaluating Bio Techne Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Techne Corp is a good investment. Please check the relationship between Bio Techne Cost Of Revenue and its Total Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Cost Of Revenue vs Total Revenue
Cost Of Revenue vs Total Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Techne Corp Cost Of Revenue account and Total Revenue. At this time, the significance of the direction appears to have totally related.
The correlation between Bio Techne's Cost Of Revenue and Total Revenue is 1.0. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Bio Techne Corp, assuming nothing else is changed. The correlation between historical values of Bio Techne's Cost Of Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Bio Techne Corp are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Cost Of Revenue i.e., Bio Techne's Cost Of Revenue and Total Revenue go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Cost Of Revenue
Cost of Revenue is found on Bio Techne Corp income statement and represents the costs associated with goods and services Bio Techne provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Revenue
Total revenue comprises all receipts Bio Techne Corp generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most indicators from Bio Techne's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Techne Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. The Bio Techne's current Selling General Administrative is estimated to increase to about 416.7 M. The Bio Techne's current Tax Provision is estimated to increase to about 24.5 M
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 1.1B | 1.1B | 1.2B | 1.2B | Depreciation And Amortization | 101.1M | 107.2M | 111.7M | 117.3M |
Bio Techne fundamental ratios Correlations
Click cells to compare fundamentals
Bio Techne Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Techne fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.0B | 2.3B | 2.3B | 2.6B | 2.7B | 2.8B | |
Short Long Term Debt Total | 433.5M | 420.6M | 326.0M | 455.0M | 419.5M | 440.5M | |
Other Current Liab | 8.3M | 62.9M | 69.2M | 45.3M | 63.9M | 67.1M | |
Total Current Liabilities | 106.7M | 152.3M | 176.0M | 128.5M | 159.4M | 167.3M | |
Total Stockholder Equity | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B | 2.2B | |
Property Plant And Equipment Net | 248.3M | 281.7M | 288.8M | 324.5M | 342.4M | 359.6M | |
Net Debt | 286.9M | 221.5M | 153.4M | 274.4M | 267.7M | 281.1M | |
Retained Earnings | 1.1B | 1.1B | 1.1B | 1.3B | 1.3B | 1.4B | |
Cash | 146.6M | 199.1M | 172.6M | 180.6M | 151.8M | 89.5M | |
Non Current Assets Total | 1.5B | 1.8B | 1.7B | 2.0B | 2.1B | 2.2B | |
Non Currrent Assets Other | 13.5M | 11.6M | (88.2M) | 285.3M | 12.1M | 16.3M | |
Cash And Short Term Investments | 270.9M | 231.6M | 247.0M | 204.3M | 152.9M | 137.1M | |
Net Receivables | 122.5M | 145.4M | 194.5M | 218.5M | 241.4M | 253.5M | |
Common Stock Shares Outstanding | 157.6M | 161.9M | 164.1M | 161.9M | 160.8M | 169.2M | |
Liabilities And Stockholders Equity | 2.0B | 2.3B | 2.3B | 2.6B | 2.7B | 2.8B | |
Non Current Liabilities Total | 539.7M | 539.4M | 417.8M | 543.7M | 475.6M | 499.4M | |
Inventory | 103.2M | 116.7M | 141.1M | 171.6M | 179.7M | 188.7M | |
Other Current Assets | 24.3M | 16.9M | 22.9M | 27.1M | 43.4M | 45.6M | |
Other Stockholder Equity | 420.5M | 534.4M | 653.7M | 721.5M | 820.3M | 861.4M | |
Total Liab | 646.4M | 691.7M | 593.8M | 672.2M | 635.0M | 666.8M | |
Total Current Assets | 520.9M | 510.6M | 605.6M | 621.5M | 617.4M | 648.3M | |
Short Term Debt | 22.0M | 35.7M | 36.4M | 22.4M | 25.8M | 27.1M | |
Accounts Payable | 63.3M | 29.4M | 33.9M | 25.7M | 38.0M | 39.9M | |
Intangible Assets | 516.5M | 616.0M | 531.5M | 534.6M | 507.1M | 532.4M | |
Property Plant And Equipment Gross | 248.3M | 281.7M | 288.8M | 324.5M | 599.0M | 628.9M | |
Accumulated Other Comprehensive Income | (97.2M) | (57.3M) | (75.2M) | (66.1M) | (78.3M) | (74.4M) | |
Common Stock Total Equity | 385K | 390K | 392K | 1.6M | 1.8M | 1.9M | |
Short Term Investments | 124.3M | 32.5M | 74.5M | 23.7M | 1.1M | 1.0M | |
Common Stock | 385K | 390K | 392K | 1.6M | 1.6M | 1.7M | |
Other Liab | 110.9M | 143.0M | 116.2M | 99.9M | 114.9M | 97.2M | |
Other Assets | 13.5M | 11.6M | 46.8M | 12.6M | 14.5M | 8.8M | |
Long Term Debt | 344.2M | 328.8M | 243.4M | 350M | 319M | 335.0M | |
Property Plant Equipment | 248.3M | 281.7M | 288.8M | 226.2M | 260.1M | 139.9M | |
Good Will | 728.3M | 843.1M | 822.1M | 872.7M | 972.7M | 1.0B | |
Current Deferred Revenue | 13.0M | 19.0M | 23.4M | 23.1M | 27.9M | 29.3M | |
Net Tangible Assets | 136.3M | 112.2M | 347.4M | 652.9M | 587.6M | 617.0M | |
Retained Earnings Total Equity | 1.1B | 1.1B | 1.1B | 1.3B | 1.5B | 812.3M | |
Capital Surpluse | 420.5M | 534.4M | 653.7M | 721.5M | 829.8M | 871.3M | |
Deferred Long Term Liab | 101.1M | 93.1M | 99.0M | 89.0M | 102.3M | 67.5M |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.